Literature DB >> 19140316

[Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer].

E A Anedchenko, A A Dmitriev, G S Krasnov, T T Kondrat'eva, E P Kopantsev, T V Vinogradova, M V Zinov'eva, I B Zborovskaia, B E Polotskiĭ, O V Sakharova, V I Kashuba, E R Zabarovskiĭ, V N Senchenko.   

Abstract

Chromosomal and genome abnormalities of 3p are frequent events in many epithelial tumours, including lung cancer. Several critical regions with high frequency of hemi--and homozygous deletions in tumours were detected on 3p and more then 20 different cancer-related genes were identified in 3p21.3 locus. Real-time PCR was used to measure mRNA level of tumour-suppressor genes and candidates in 3p21.3 (RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 in basic types of non-small cell lung cancer (NSCLC)--squamous cell lung cancer (SCC) and lung adenocarcinoma (AC). Significant (from 2 to 100 times) and frequent (from 44 to 100%) mRNA level decrease was shown in NSCLC. Level and frequency of mRNA decrease for all genes depended on histological type of NSCLC. Down-regulation of RASSF1A and ITGA9 was associated significantly with AC progression, the same tendency was found for genes RBSP3/CTDSPL, NPRL2/G21, HYAL1 and HYAL2. On the contrary, down-regulation of all genes in SCC was not associated with clinical stages, tumor cells differentiation and metastases in lymph nodes. Significant decrease of RBSP3/CTDSPL, NPRL2/G21, ITGA9, HYAL1 and HYAL2 mRNA levels (on average, 5-13 times) with high frequency (83-100%) was already shown at the first stage of SCC. Simultaneous decrease of all six genes mRNA level was found in the same tumor samples and was not depended on their localization on 3p21.3 and functions of the proteins. Spearman's correlation coefficient r(s) was from 0.63 to 0.91, P < 0.001. Co-regulation of gene pairs ITGA9 and HYAL2, HYAL1 and HYAL2, which mediate cell-cell adhesion and cell-matrix interaction, was suggested based on the obtained data. It was shown that genetic and epigenetic mechanisms were important for down-regulation of RBSP3/CTDSPL and ITGA9 genes. These results supported the hypothesis on simultaneous inactivation of cluster cancer-related genes in extended 3p21.3 locus during development and progression of lung cancer and other epithelial tumors. Significant and frequent decrease of mRNA level of six genes in SCC could be important for development of specific biomarker sets for early SCC diagnosis and new therapeutic approaches/strategies for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19140316

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  19 in total

Review 1.  SEA you later alli-GATOR--a dynamic regulator of the TORC1 stress response pathway.

Authors:  Svetlana Dokudovskaya; Michael P Rout
Journal:  J Cell Sci       Date:  2015-05-01       Impact factor: 5.285

2.  Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer.

Authors:  Vera N Senchenko; Natalia P Kisseljova; Tatyana A Ivanova; Alexey A Dmitriev; George S Krasnov; Anna V Kudryavtseva; Grigory V Panasenko; Evgeny B Tsitrin; Michael I Lerman; Fyodor L Kisseljov; Vladimir I Kashuba; Eugene R Zabarovsky
Journal:  Epigenetics       Date:  2013-03-11       Impact factor: 4.528

3.  Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells.

Authors:  Eliana Noelia Alonso; Manuela Orozco; Alvaro Eloy Nieto; Gabriela Andrea Balogh
Journal:  J Med Food       Date:  2013-07       Impact factor: 2.786

4.  Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.

Authors:  Dorota Pastuszak-Lewandoska; Jacek Kordiak; Adam Antczak; Monika Migdalska-Sęk; Karolina H Czarnecka; Paweł Górski; Ewa Nawrot; Justyna M Kiszałkiewicz; Daria Domańska-Senderowska; Ewa Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-06-10       Impact factor: 3.064

5.  Small suitability of the DLEC1, MLH1 and TUSC4 mRNA expression analysis as potential prognostic or differentiating markers for NSCLC patients in the Polish population.

Authors:  Jacek Kordiak; Karolina H Czarnecka; Dorota Pastuszak-Lewandoska; Adam Antczak; Monika Migdalska-Sęk; Ewa Nawrot; Daria Domańska-Senderowska; Justyna Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  J Genet       Date:  2017-06       Impact factor: 1.166

6.  Differential expression of CHL1 gene during development of major human cancers.

Authors:  Vera N Senchenko; George S Krasnov; Alexey A Dmitriev; Anna V Kudryavtseva; Ekaterina A Anedchenko; Eleonora A Braga; Irina V Pronina; Tatiana T Kondratieva; Sergey V Ivanov; Eugene R Zabarovsky; Michael I Lerman
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

7.  MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.

Authors:  Y-S Zheng; H Zhang; X-J Zhang; D-D Feng; X-Q Luo; C-W Zeng; K-Y Lin; H Zhou; L-H Qu; P Zhang; Y-Q Chen
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

8.  Classification of non-small cell lung cancer based on copy number alterations.

Authors:  Bi-Qing Li; Jin You; Tao Huang; Yu-Dong Cai
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

10.  Combined analysis with copy number variation identifies risk loci in lung cancer.

Authors:  Xinlei Li; Xianfeng Chen; Guohong Hu; Yang Liu; Zhenguo Zhang; Ping Wang; You Zhou; Xianfu Yi; Jie Zhang; Yufei Zhu; Zejun Wei; Fei Yuan; Guoping Zhao; Jun Zhu; Landian Hu; Xiangyin Kong
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.